← Eichor
Condition: Epstein Barr Virus Infections Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Epstein Barr Virus Infections

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/Phase 3 · 12 location(s) · Merck Sharp & Dohme LLC · NCT07570173Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Affiliated Hospital of Guangdong Medical University · NCT06940960NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06503094Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase N/A · 1 location(s) · Institut Pasteur du Cambodge · NCT07358910EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Phase 1 · 4 location(s) · Baylor College of Medicine · NCT04664179Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infec
Phase 1/Phase 2 · 1 location(s) · LucasBio · NCT07670468Third Party Viral Specific T-cells (VSTs)
Phase 2 · 4 location(s) · Children's Hospital Medical Center, Cincinnati · NCT02532452Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leu
Phase 3 · 460 location(s) · Alliance for Clinical Trials in Oncology · NCT03150693A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
Phase 1/Phase 2 · 1 location(s) · Zhimin Zhai · NCT07306156Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
Phase 2 · 2 location(s) · Fudan University · NCT07381738Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06696833A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Phase 1/Phase 2 · 9 location(s) · Juventas Cell Therapy Ltd. · NCT05667506Mechanisms of Persistent Fatigue
Phase N/A · 1 location(s) · University Hospital, Akershus · NCT07394855Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
Phase 4 · 12 location(s) · Labo'Life · NCT04308278CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 7 location(s) · British Columbia Cancer Agency · NCT06208735Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NA · 1 location(s) · University of Chicago · NCT06785324Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Phase 2/Phase 3 · 27 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06764238Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir
Phase 4 · 1 location(s) · Beijing Children's Hospital · NCT07029958Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT06119256Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL
Phase 1 · 3 location(s) · Chulalongkorn University · NCT07078929AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relap
Phase 1 · 8 location(s) · Shanghai Pharmaceutical Group Biological Therapy Technology · NCT06927466
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.